| Ytd | 21.16% | |
| 1y | 399.94% |
| Open | 82.28 | Prev Close | 81.51 | Low | 78.81 | High | 82.39 | Mkt Cap | 11.33B |
| Vol | 1.93M | Avg Vol | 2.03M | EPS | -2.27 | P/E | N/A | Forward P/E | -18.55 |
| Beta | 1.27 | Short Ratio | 7.88 | Inst. Own | 88.50% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 76.20 | 200-d Avg | 60.19 | 1yr Est | 89.08 |
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Arrowhead Pharma (NASDAQ:ARWR) wit
Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses Cardiometabolic Pipeline and Clinical Development P
US stock futures up, Nasdaq 100 gains 1%. Biohaven (BHVN) shares down after BofA downgrade and enrol
Large-cap pharma is back in the deal market. AbbVie's (NASDAQ: ABBV | ABBV Price Prediction) pending
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that the European Commission (EC) has
Leerink Partners analyst Mani Foroohar maintains Arrowhead Pharma (NASDAQ:ARWR) with a Market Per